Dergiler / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 1

Mucormycosis: a 10-year experience at a tertiary care center in Turkey

Sayfa
58–62
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Also, in the case of facial pain, the low mortality rate may indicate the importance of early diagnosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: Mucormycosis is a rare invasive fungal infection most commonly encountered in the immunocompromised host.
📊
Temel Bulgular & Veri:We analyzed 51 adult patients treated for mucormycosis between 2003 and 2013 and recorded at a tertiary university hospital in Turkey.
💡
Sonuç & Katkı:Also, in the case of facial pain, the low mortality rate may indicate the importance of early diagnosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:2003 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: Mucormycosis is a rare invasive fungal infection most commonly encountered in the immunocompromised host. We analyzed 51 adult patients treated for mucormycosis between 2003 and 2013 and recorded at a tertiary university hospital in Turkey. Materials and methods: We examined the following data for all patients: age, sex, predisposing disease, symptoms, treatment, surgical procedure, concomitant infections, intensive care requirement, and outcomes. Results: During the study period 51 cases of mucormycosis were documented; 54.9% of the patients were female. The mean age was 44.2 ± 18.2 years. Rhinocerebral presentation was reported in 94.1% of patients. Almost all patients (88.2%) had at least one risk factor. The common predisposing factors were hematologic malignancies (52.9%), diabetes mellitus (25.5%), and solid malignancies (5.8%). The most common initial symptoms were fever, cellulitis, and facial pain. The primary medication used was liposomal amphotericin B or conventional amphotericin B. Surgery was performed in 94.1% of patients. Mortality was 52.9%. Conclusion: Our study revealed that mucormycosis continues to be a mortal disease in about half of the cases. Our findings indicate that treatment with L-AMB is associated with a favorable response. Also, in the case of facial pain, the low mortality rate may indicate the importance of early diagnosis.

🔖

Bu Makaleye Atıf Yap

ULU, A., İNAL, A. S., KURTARAN, B., UĞUZ, A., TAŞOVA, Y., KÖMÜR, S., AKSU, H. S. Z. (2022). Mucormycosis: a 10-year experience at a tertiary care center in Turkey. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 1, 58–62. https://ajindex.com/articles/610864

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 1): 23–34
  2. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653
  3. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008; 61: i35–i39
  4. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743–1751
  5. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrau K, Lass-Florl C, Bouza E, Klimko N, Gaustad P et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859–1867
  6. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O. Increasing incidence of zygomycosis (mucormycosis), France. Emerg Infect Dis 2005; 41: 634–653
  7. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Inf Dis 2010; 14: 100–103
  8. Kara O, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematological malignancies. Int J Clin Prac 2009; 63: 134–139
  9. Arda B, Erdem A, Sipahi OR, Işıkgöz Taşbakan M, Pullukçu H, Taşbakan MS, Ceylan N, Metin DY, Midilli R, Yamazhan T et al. Mucormycosis: a retrospective evaluation of 12 cases. Mikrobiyol Bul 2011; 45: 504–511
  10. Ketenci I, Unlu Y, Kaya H, Somdaş MA, Kontaş O, Öztürk M, Vural A. Rhinocerebral mucormycosis: experience in 14 patients. J Laryngol Otol 2011; 125: 1–9
  11. Zeka AN, Taşbakan M, Pullukçu H, Sipahi OR, Yamazhan T, Arda B. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013; 47: 708– 716
  12. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360
  13. Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, Mari